SAN CLEMENTE, Calif., Sept. 1, 2006 (PRIMEZONE) -- There is a growing worldwide demand for more efficacious pharmaceutical agents to combat glaucoma and age-related macular degeneration. In addition, there is demand for more critical and accurate medical devices for the detection and removal of cataracts. The Company’s effort to respond with cost effective and novel solutions has garnered significant attention from European investors.
